Clinical trial NCT00796744 - References

Diabetic Foot — Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Citation(s)

•   Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers KE, Nigh KA, diZerega GS
  NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wou
•   Rodgers K, Xiong S, Felix J, Roda N, Espinoza T, Maldonado S, Dizerega G
  Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen. 2001 May-Jun;9(3):238-47.
•   Rodgers KE, Ellefson DD, Espinoza T, Roda N, Maldonado S, Dizerega GS
  Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat. Wound Repair Regen. 2005 May-Jun;13(3):309-17.
•   Rodgers KE, Espinoza T, Felix J, Roda N, Maldonado S, diZerega G
  Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar;111(3):1195-206.
•   Rodgers KE, Roda N, Felix JE, Espinoza T, Maldonado S, diZerega G
  Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Exp Dermatol. 2003 Dec;12(6):784-90.

Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial to Evaluate the Safety and Effectiveness of DSC127 in Treating Subjects With Diabetic Ulcers

Details for clinical trial NCT00796744